Literature DB >> 33689693

Circulating calprotectin as biomarker in neutrophil-related inflammation: Pre-analytical recommendations and reference values according to sample type.

Marnix Mylemans1, Louis Nevejan1, Stefanie Van Den Bremt1, Muriel Stubbe2, Bert Vander Cruyssen2, Christina Moulakakis3, Heike Berthold3, Christian Konrad3, Xavier Bossuyt4, Lieve Van Hoovels5.   

Abstract

BACKGROUND: Calprotectin (CLP) is a promising biomarker for the evaluation of neutrophil-related inflammation. Our aim was to establish reference values for circulating CLP in different sample types and to study the effect of pre-analytical variables.
METHODS: Reference values were determined in 100 healthy individuals. Pre-analytical variables were evaluated in 10 healthy controls and four rheumatoid arthritis patients with active disease and covered sample type (serum with/without gel separator, heparin, EDTA and citrate plasma), pre-centrifugation time (<2 h, 6 h, 24 h), storage condition (2-8 °C, 18-25 °C, 30 °C) and storage time (24 h, 72 h, 7 days). CLP measurements were performed with the EliA™Calprotectin 2 assay on Phadia™200 (Thermo Fisher Scientific).
RESULTS: In healthy controls, baseline CLP concentrations in serum were more than double the concentration in EDTA and citrate plasma (0.909 µg/mL versus 0.259 µg/mL and 0.261 µg/mL respectively). Heparin, EDTA and citrate stabilized CLP concentrations for up to 6 h before centrifugation, whereas significant increases in CLP levels were observed when serum was left untreated during that time period.
CONCLUSION: Clinical studies on circulating CLP need to apply sample type-specific reference values and decision limits. To obtain reproducible CLP results in serum, more stringent pre-analytical sample handling instructions are needed.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarker; Circulating calprotectin; Neutrophil-related inflammation; Pre-analytical phase; Reference values

Year:  2021        PMID: 33689693     DOI: 10.1016/j.cca.2021.02.022

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  4 in total

1.  Circulating Calprotectin as a Predictive and Severity Biomarker in Patients with COVID-19.

Authors:  Gary L Norman; Sherwin A Navaz; Yogendra Kanthi; Roger Albesa; Michael Mahler; Jason S Knight; Yu Zuo
Journal:  Diagnostics (Basel)       Date:  2022-05-27

2.  Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients.

Authors:  Nicolas Chapuis; Nusaibah Ibrahimi; Thibaut Belmondo; Claire Goulvestre; Anne-Emmanuelle Berger; Alice-Andrée Mariaggi; Muriel Andrieu; Camille Chenevier-Gobeaux; Arnaud Bayle; Lydia Campos; Cherifa Cheurfa; Richard Chocron; Jean-Luc Diehl; Benoît Doumenc; Jérôme Duchemin; Manon Duprat; Fabien François; Nicolas Gendron; Tristant Mirault; Frédéric Pène; Aurélien Philippe; Fanny Pommeret; Olivier Sanchez; David M Smadja; Tali-Anne Szwebel; Aymeric Silvin; Florent Ginhoux; Ludovic Lacroix; Gérôme Jules-Clément; Sarobidy Rapeteramana; Colette Mavier; Laura Steller; Barbara Perniconi; Fabrice André; Damien Drubay; Michaela Fontenay; Sophie Hüe; Stéphane Paul; Eric Solary
Journal:  EBioMedicine       Date:  2022-05-26       Impact factor: 11.205

3.  Circulating levels of calprotectin, a signature of neutrophil activation in prediction of severe respiratory failure in COVID-19 patients: a multicenter, prospective study (CalCov study).

Authors:  Luis García de Guadiana-Romualdo; Carlos Rodríguez Rojas; Daniel Morell-García; David Andaluz-Ojeda; María Dolores Rodríguez Mulero; Enrique Rodríguez-Borja; Antonieta Ballesteros-Vizoso; María Dolores Calvo; Lourdes Albert-Botella; Adela Pozo Giráldez; Isabel Llompart-Alabern; Cristina Bolado Jiménez; Marta Hernández Olivo; Lucía Fernández Presa; Juan Ortega-Pérez; María José Fora Romero; Valerio Campos-Rodríguez; Andrea Ballester Férriz; Alexandra M Guiu-Martí; Leyre Pinilla Arribas; María Galindo Martínez; Edwin R Puerto-Lara; Ana Belen López Tarazaga; María Salomé Ros Braquehais; Leonor Nogales Martín; Celia Juez Santamaría; Wysalli Trapiello Fernández; Virginia Espinilla Fernández; Aleksandra Havelka; María Dolores Albaladejo-Otón
Journal:  Inflamm Res       Date:  2021-10-30       Impact factor: 6.986

4.  Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy.

Authors:  Michael Gernert; Marc Schmalzing; Hans-Peter Tony; Patrick-Pascal Strunz; Eva Christina Schwaneck; Matthias Fröhlich
Journal:  Arthritis Res Ther       Date:  2022-08-19       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.